Published in Cancer on December 01, 2007
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer (2009) 1.43
Treatment of metastatic renal cell carcinoma. Nat Rev Urol (2010) 1.24
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res (2014) 1.15
A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets (2012) 1.12
Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist (2014) 1.11
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer (2011) 1.08
Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. Can Urol Assoc J (2008) 1.04
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J (2015) 1.03
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
[Renal cell carcinoma 2008. Histopathology, molecular genetics and new therapeutic options]. Pathologe (2008) 0.98
Management of kidney cancer: canadian kidney cancer forum consensus update 2011. Can Urol Assoc J (2012) 0.92
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist (2010) 0.89
Updates on novel therapies for metastatic renal cell carcinoma. Ther Adv Med Oncol (2010) 0.89
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2015) 0.88
Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha. World J Urol (2010) 0.87
Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Transl Androl Urol (2015) 0.86
Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics (2008) 0.84
Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review. Can Urol Assoc J (2010) 0.84
Systemic therapy for advanced renal cell carcinoma. Ther Adv Med Oncol (2009) 0.84
Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Pharmgenomics Pers Med (2014) 0.84
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol (2011) 0.83
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer (2012) 0.83
Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Manag Res (2010) 0.82
Pazopanib trial data cannot support first-line use. Nat Rev Urol (2010) 0.81
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol (2010) 0.81
Sorafenib in the management of metastatic renal cell carcinoma. Curr Oncol (2009) 0.79
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013. Can Urol Assoc J (2013) 0.79
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol (2010) 0.77
The times they are a-changin' (Bob Dylan, 1964). Cancer (2007) 0.76
Update on vaccine development for renal cell cancer. Open Access J Urol (2010) 0.76
Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother (2016) 0.75
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? J Kidney Cancer VHL (2014) 0.75
State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol (2009) 0.75
Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis. Onco Targets Ther (2016) 0.75
Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma. Oncol Lett (2015) 0.75
Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. Mol Clin Oncol (2017) 0.75
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Renal cell carcinoma. Lancet (2009) 6.92
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol (2007) 3.35
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol (2007) 2.86
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol (2008) 2.85
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol (2010) 2.74
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res (2004) 2.52
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol (2003) 2.44
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol (2012) 2.26
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol (2011) 2.17
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol (2008) 2.12
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol (2004) 2.05
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol (2004) 1.86
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol (2010) 1.80
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol (2012) 1.74
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst (2012) 1.72
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer (2005) 1.67
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer (2006) 1.65
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int (2012) 1.64
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood (2003) 1.62
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst (2008) 1.53
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Laparoscopic radical prostatectomy in renal transplant recipients. Urology (2009) 1.52
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol (2008) 1.49
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer (2011) 1.45
Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology (2009) 1.45
Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology (2006) 1.45
Impact of diagnostic delay in testis cancer: results of a large population-based study. Eur Urol (2007) 1.44
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun (2004) 1.43
[Kidney tumors]. Prog Urol (2007) 1.43
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab (2012) 1.42
How to interpret phase II data for everolimus plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.41
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. Arch Esp Urol (2010) 1.41
Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol (2007) 1.39
Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol (2005) 1.38
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist (2012) 1.34
The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol (2009) 1.34
Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol (2008) 1.33
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol (2005) 1.30